Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




ctDNA Blood Test to Help Personalize Postsurgical Colon Cancer Treatment

By LabMedica International staff writers
Posted on 29 Oct 2025

For patients with Stage 3 colon cancer, current chemotherapy approaches are highly toxic and lack personalization. More...

Standard treatment involves months of dual-agent chemotherapy, which often causes serious side effects, including long-term nerve damage. Now, a new study suggests that circulating tumor DNA (ctDNA)—tiny fragments of genetic material shed by tumors into the bloodstream—can help doctors tailor chemotherapy based on recurrence risk, marking a major step toward personalized cancer care.

The study, known as the DYNAMIC-III trial, was a multi-institutional phase II/III clinical investigation co-led by the Johns Hopkins Kimmel Cancer Center (Baltimore, MD, USA) and included approximately 20 clinical sites across Australia and Canada. The study evaluated whether ctDNA-guided treatment could optimize chemotherapy use for patients with Stage 3 colon cancer, which has spread to nearby lymph nodes but not distant organs.

Researchers tested blood samples for ctDNA five to six weeks after surgery. Patients who tested positive for ctDNA were considered at higher risk for recurrence and received more intensive chemotherapy, while those who tested negative received less aggressive treatment. A total of 1,002 patients were enrolled: 500 received standard management, while 502 were assigned to ctDNA-guided care. In the ctDNA-guided group, positive patients received escalated therapy—half with triple-drug FOLFOXIRI and 43% with six months of oxaliplatin-based doublet therapy—while ctDNA-negative patients had treatment de-escalated to shorter or less frequent regimens.

Researchers then tracked recurrence-free survival over two and three years, respectively, for ctDNA-positive and ctDNA-negative patients. After an average follow-up of 47 months, ctDNA-negative patients experienced significantly fewer recurrences (49%) compared to ctDNA-positive patients (87%). For ctDNA-negative patients, receiving less chemotherapy reduced oxaliplatin exposure (34.8% vs. 88.6%), hospitalizations (8.5% vs. 13.2%), and high-grade adverse events (6.2% vs. 10.6%) without a major difference in recurrence-free survival (85.3% vs. 88.1%).

However, intensifying treatment for ctDNA-positive patients did not improve recurrence-free survival (51% vs. 61%), highlighting a need for new therapies for those with persistent ctDNA. The findings, published in Nature Medicine, showed that persistent ctDNA after treatment was strongly linked to poor outcomes, with a three-year recurrence-free survival of just 14%, compared to 79% in patients who cleared ctDNA after chemotherapy. Among ctDNA-negative participants, 13.5% experienced recurrence, primarily in the lungs and peritoneum—areas known to shed less tumor DNA into the bloodstream. Researchers believe ctDNA testing could soon guide real-time treatment decisions for colon cancer and other tumor types.

“This study demonstrates that likely, in the near future, ctDNA can be used to help make clinical decisions for patients with colon cancers,” said Yuxuan Wang, M.D., Ph.D., assistant professor of oncology at Johns Hopkins. “Conceivably, we can use ctDNA in other tumor types to inform patient management the same way.”

Related Links:
Johns Hopkins Kimmel Cancer Center


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Automated Immunoassay Analyzer
SuperFlex™
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.